Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry.
Khava I E IbragimovaSandra M E GeurtsMarissa MeegdesFrans ErdkampJoan B HeijnsJolien TolBirgit E P J VriensMarcus W DercksenKirsten N A AalderingManon J A E PepelsLinda van de WinkelNatascha A J B PetersNathalie J A Teeuwen-DedroogIngeborg J H VriensVivianne C G Tjan-HeijnenPublished in: Breast cancer research and treatment (2023)
Survival times for later lines of therapy are surprisingly long and justify the use of multiple lines of systemic therapy in well-selected patients with HER2 + ABC. Our real-world evidence adds valuable observations to the accumulating evidence that within HER2 + ABC, the HR status defines two distinct disease subtypes.